주식회사 이뮤닉
DE ˙ DB
€16.63 ↓ -16.55 (-49.87%)
2019-04-18
주가
SecurityDE:10V / Immunic, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership3,923,763 shares
Ownership 4.35%
Vanguard Group Inc ownership in 10V / Immunic, Inc.

2025-01-30 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,923,763 shares of Immunic, Inc. (DE:10V). This represents 4.35 percent ownership of the company. In their previous filing dated 2024-11-12 , Vanguard Group Inc had reported owning 4,700,016 shares, indicating a decrease of -16.52 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-01-30 2025-01-30 13G/A 4,700,016 3,923,763 -16.52 4.35 -16.51
2024-11-12 2024-11-12 13G/A 4,700,016 4,700,016 0.00 5.21 0.00
2024-11-04 2024-11-04 13G/A 4,700,016 5.21

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F IMMUNIC COM 4525EP101 5,020,337 675,232 15.54 2,681 -30.06 0.0000
2025-11-07 2025-09-30 13F IMMUNIC COM 4525EP101 4,345,105 219,957 5.33 3,832 33.10 0.0001
2025-08-11 2025-06-30 13F IMMUNIC COM 4525EP101 4,125,148 193,600 4.92 2,879 -32.81 0.0000
2025-05-09 2025-03-31 13F IMMUNIC COM 4525EP101 3,931,548 7,785 0.20 4,285 9.23 0.0001
2025-02-11 2024-12-31 13F IMMUNIC COM 4525EP101 3,923,763 -776,253 -16.52 3,924 -49.41 0.0001
2024-11-13 2024-09-30 13F IMMUNIC COM 4525EP101 4,700,016 959,969 25.67 7,755 86.82 0.0001
2024-08-13 2024-06-30 13F IMMUNIC COM 4525EP101 3,740,047 346,000 10.19 4,151 -7.34 0.0001
2024-05-10 2024-03-31 13F IMMUNIC COM 4525EP101 3,394,047 1,703,047 100.71 4,480 76.66 0.0001
2024-03-11 2023-12-31 13F/A-1 IMMUNIC COM 4525EP101 1,691,000 28,411 1.71 2,536 3.76 0.0001
2024-02-14 2023-12-31 13F IMMUNIC COM 4525EP101 1,691,000 28,411 2,536 0.0000
2023-12-18 2023-09-30 13F/A-1 IMMUNIC COM 4525EP101 1,662,589 -13,685 -0.82 2,444 -41.91 0.0001
2023-11-14 2023-09-30 13F IMMUNIC COM 4525EP101 1,662,589 -13,685 2,444 0.0001
2023-08-14 2023-06-30 13F IMMUNIC COM 4525EP101 1,676,274 170,600 11.33 4,207 87.56 0.0001
2023-07-14 2023-03-31 13F/A-1 IMMUNIC COM 4525EP101 1,505,674 434,254 40.53 2,243 49.63 0.0001
2023-05-15 2023-03-31 13F IMMUNIC COM 4525EP101 1,505,674 434,254 2,243 0.0000
2023-02-10 2022-12-31 13F IMMUNIC COM 4525EP101 1,071,420 76,749 7.72 1,500 -52.31 0.0000
2022-11-14 2022-09-30 13F IMMUNIC COM 4525EP101 994,671 115,649 13.16 3,143 3.05 0.0001
2022-08-12 2022-06-30 13F IMMUNIC COM 4525EP101 879,022 -77,675 -8.12 3,050 -71.79 0.0001
2022-05-13 2022-03-31 13F IMMUNIC COM 4525EP101 956,697 54,867 6.08 10,811 25.27 0.0003
2022-02-14 2021-12-31 13F IMMUNIC COM 4525EP101 901,830 20,625 2.34 8,630 10.67 0.0002
2021-11-12 2021-09-30 13F IMMUNIC COM 4525EP101 881,205 169,432 23.80 7,798 -10.63 0.0002
2021-08-13 2021-06-30 13F IMMUNIC COM 4525EP101 711,773 -20,127 -2.75 8,726 -25.21 0.0002
2021-05-14 2021-03-31 13F IMMUNIC COM 4525EP101 731,900 48,537 7.10 11,667 11.67 0.0003
2021-02-12 2020-12-31 13F IMMUNIC COM 4525EP101 683,363 33,157 5.10 10,448 -13.47 0.0003
2020-11-16 2020-09-30 13F IMMUNIC COM 4525EP101 650,206 402,278 162.26 12,074 301.80 0.0004
2020-08-14 2020-06-30 13F IMMUNIC COM 4525EP101 247,928 236,408 2,052.15 3,005 4,192.86 0.0001
2020-05-15 2020-03-31 13F IMMUNIC COM 4525EP101 11,520 0 0.00 70 -37.50 0.0000
2020-02-14 2019-12-31 13F IMMUNIC COM 4525EP101 11,520 0 0.00 112 -3.45 0.0000
2019-11-14 2019-09-30 13F IMMUNIC COM 4525EP101 11,520 -3 -0.03 116 -12.12 0.0000
2019-08-14 2019-06-30 13F IMMUNIC COM 4525EP101 11,523 -561,429 -97.99 132 16.81 0.0000
2019-05-15 2019-03-31 13F VITAL THERAPIES COM 92847R104 572,952 -119,970 -17.31 113 -12.40 0.0000
2019-02-14 2018-12-31 13F VITAL THERAPIES COM 92847R104 692,922 -788,986 -53.24 129 -68.38 0.0000
2018-12-13 2018-09-30 13F/A-2 VITAL THERAPIES COM 92847R104 1,481,908 148,016 11.10 408 -95.53 0.0000
2018-11-23 2018-09-30 13F/A-1 VITAL THERAPIES COM 92847R104 1,481,908 0 408 0.0000
2018-11-14 2018-09-30 13F VITAL THERAPIES COM 92847R104 1,481,908 148,016 408
2018-08-14 2018-06-30 13F VITAL THERAPIES COM 92847R104 1,333,892 158,672 13.50 9,137 14.34 0.0004
2018-05-15 2018-03-31 13F VITAL THERAPIES COM 92847R104 1,175,220 76,755 6.99 7,991 22.26 0.0003
2018-02-14 2017-12-31 13F VITAL THERAPIES COM 92847R104 1,098,465 181,604 19.81 6,536 41.17 0.0003
2017-11-14 2017-09-30 13F VITAL THERAPIES COM 92847R104 916,861 178,340 24.15 4,630 116.25 0.0002
2017-08-24 2017-06-30 13F/A-1 VITAL THERAPIES COM 92847R104 738,521 -107,337 -12.69 2,141 -36.71 0.0001
2017-08-11 2017-06-30 13F VITAL THERAPIES COM 92847R104 738,521 -107,337 2,141
2017-05-12 2017-03-31 13F VITAL THERAPIES COM 92847R104 845,858 13,654 1.64 3,383 -6.55 0.0002
2017-02-14 2016-12-31 13F VITAL THERAPIES COM 92847R104 832,204 49,803 6.37 3,620 -24.39 0.0002
2016-11-14 2016-09-30 13F VITAL THERAPIES COM 92847R104 782,401 4,592 0.59 4,788 -0.71 0.0003
2016-08-10 2016-06-30 13F VITAL THERAPIES COM 92847R104 777,809 14,645 1.92 4,822 -30.34 0.0003
2016-05-13 2016-03-31 13F VITAL THERAPIES COM 92847R104 763,164 56,105 7.93 6,922 -15.03 0.0004
2016-02-08 2015-12-31 13F VITAL THERAPIES COM 92847R104 707,059 140,961 24.90 8,146 256.19 0.0005
2015-11-12 2015-09-30 13F/A-1 VITAL THERAPIES COM 92847R104 566,098 134,396 31.13 2,287 -74.89 0.0001
2015-08-13 2015-06-30 13F VITAL THERAPIES COM 92847R104 431,702 32,945 8.26 9,109 -8.66 0.0006
2015-05-15 2015-03-31 13F/A-1 VITAL THERAPIES COM 92847R104 398,757 33,221 9.09 9,973 9.44 0.0007
2015-05-14 2015-03-31 13F VITAL THERAPIES COM 92847R104 398,757 9,973
2015-02-12 2014-12-31 13F VITAL THERAPIES COM 92847R104 365,536 266,138 267.75 9,113 349.14 0.0007
2014-11-12 2014-09-30 13F VITAL THERAPIES COM 92847R104 99,398 54,264 120.23 2,029 64.96 0.0002
2014-08-11 2014-06-30 13F VITAL THERAPIES COM 92847R104 45,134 45,134 1,230 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.